Overcoming preclinical challenges around radionuclide selection, biodistribution, circulation, and clearance.
The rapid growth of radiopharmaceuticals is creating new opportunities for oncology drug developers, but success requires more than attaching a radionuclide to a promising in vitro compound.
View this webinar and learn how to:
- Understand the challenges of translating promising in vitro candidates into radiopharmaceuticals.
- Identify how pre-targeting and other optimization strategies can support successful radiopharmaceutical development.
- Assess the impact of radionuclide and chelator selection on candidate design.
- Explain how biodistribution, circulation time, and clearance influence therapeutic and diagnostic performance.



